Two drugs have been rejected for use on the NHS to treat breast cancer when combined with other therapies following a consultation.
NICE turned down an application to use Tyverb (lapatinib) and Herceptin (trastuzumab) in combination with an aromatase inhibitor, another type of breast cancer treatment.
The draft guidance, which is open to consultation, does not recommend using the drugs in this way for treating advanced breast cancer that is both hormone-receptor and HER2-positive.
Tyverb would cost around £28,000 per patient for a year of treatment in this setting, while Herceptin - which is approved on the NHS for other breast cancers - would cost about £26,000.
NICE chief executive Sir Andrew Dillon said the data relating to whether patients lived longer with the drugs was uncertain.
Almost 46,000 women in the UK are diagnosed with breast cancer every year, and up to 80% have hormone receptor-positive breast cancer, which means that cancer cells depend on female hormones, including oestrogen, to grow.
These tumours can also sometimes be HER2-positive, which means that cells grow and divide quicker and the cancer is more aggressive.
NICE also published final advice to the NHS on the use of Avastin (bevacizumab) for bowel cancer that has spread to other organs, confirming previous pieces of guidance rejecting the drug.